Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2020-01-29 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated January 29, 2020, announcing a clinical research agreement between Onxeo and Gustave Roussy to conduct a Phase 1b/2 trial (REVOCAN) for the drug AsiDNA™ in recurrent ovarian cancer. This announcement details a specific business development, a clinical trial initiation, and partnership, which is characteristic of a general corporate announcement or news release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is a specific corporate action announcement that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it falls best under the general Regulatory Filings (RNS) category, which serves as a broad category for significant, non-standard announcements, or potentially Investor Presentation (IP) if it were structured as a presentation, but here it reads like a formal news release about a partnership and trial initiation. Given the options, RNS is the most appropriate fallback for a significant, non-standard corporate update that isn't a standard financial report or management disclosure.
2020-01-29 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document announces a specific business development: Onxeo entering a Clinical Research Agreement with Gustave Roussy for a clinical trial (REVOCAN study) involving their drug AsiDNA™. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific corporate announcement detailing a strategic partnership and clinical development milestone. Among the provided codes, 'LTR' (Legal Proceedings Report) is incorrect as this is a collaboration, not a lawsuit. 'CAP' (Capital/Financing Update) is incorrect as no fundraising is mentioned. The closest fit for a significant, non-financial, non-governance corporate update that doesn't fit other specific categories is often categorized under general regulatory announcements or news releases. Since this is a specific announcement about a clinical trial agreement, and there isn't a dedicated 'Clinical Trial Update' code, it falls best under 'RNS' (Regulatory Filings/General Regulatory Announcements) as a material event disclosure, or potentially 'LTR' if interpreted broadly as a report on a significant operational/legal agreement, but RNS is the safer general disclosure category when specific codes like 'M&A' or 'CAP' don't apply. Given the nature of biotech announcements, RNS serves as the best catch-all for material operational news that isn't a standard financial report.
2020-01-29 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated January 28, 2020, announcing that the company Onxeo will present data on its drug candidate OX401 at the 'PARP & DDR Inhibitors Summit 2020'. It details the scientific content of the presentation and provides links to the presentation slides and a poster. This type of announcement, which publicizes participation in a scientific conference or event where research findings are shared, is best classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about an upcoming presentation. Since the text is a press release announcing participation and providing context about their pipeline (AsiDNA™, OX401, belinostat), it functions as an update for investors regarding scientific progress and upcoming disclosures. Given the options, it is not a formal regulatory filing (10-K, IR, ER), nor is it a management change (MANG) or dividend notice (DIV). It is an announcement related to investor communication about scientific data. While it could potentially be RNS (Regulatory Filings) as a general announcement, the content is highly focused on presenting scientific data at a specific industry event, which aligns closely with the purpose of an Investor Presentation (IP) or a general update. However, since the document *is* the announcement of the presentation, and not the presentation itself, and it is a general press release format, the most fitting category for an announcement detailing scientific updates and upcoming presentations/posters at a conference is often captured under general investor communications. Given the specific nature of the content (presenting scientific data at a summit), it is a form of investor communication. If the document were the actual presentation slides, IP would be correct. As it is the press release *about* the presentation, and it contains substantial pipeline updates, it leans towards being a general update. However, in many databases, announcements about scientific presentations are often grouped with Investor Presentations or Regulatory Filings. Since it is a formal press release announcing scientific data dissemination, and it is not a standard financial report, 'RNS' (Regulatory Filings/General Announcement) is a safe fallback, but 'IP' (Investor Presentation) often covers materials related to investor outreach about pipeline progress. Given the detailed scientific content being shared via the announcement, I will classify it as an Investor Presentation (IP) as it serves the function of presenting pipeline information to investors, even if it's via a press release format announcing the event. If RNS was chosen, it would be a fallback. I will stick with IP as the primary function is investor-facing scientific update.
2020-01-28 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated January 28, 2020, announcing that the company, Onxeo, will present data on its drug candidate OX401 at the PARP & DDR Inhibitors Summit 2020. It details the scientific content of the presentation and provides links to access the presentation slides and a related poster. This is not a formal regulatory filing like a 10-K, 10-Q, or a formal earnings release (ER). It is an announcement about participation in a scientific conference and the presentation of research data. Since it is an announcement about presenting scientific/investor-related material (Investor Presentation content), and it is not a formal regulatory filing, the most appropriate category is Investor Presentation (IP), as it directly relates to the content being shared with investors/stakeholders at a summit. It is not a Report Publication Announcement (RPA) because it is announcing the presentation of data, not the publication of a formal company report (like an Annual Report or Interim Report).
2020-01-28 English
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is titled "Onxeo Publishes Shareholder Newsletter" and explicitly states that the company announces the publication of its shareholder letter. It directs the reader to the company's website to read the full letter. The document itself is short (under 5,000 characters) and serves as an announcement about the availability of another document (the shareholder letter), rather than being the detailed report itself. According to Rule #2 (The "MENU VS MEAL" Rule), when a document announces the publication of a report and directs the user to a link, it should be classified as a Report Publication Announcement (RPA).
2020-01-20 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is titled "Onxeo publie sa nouvelle lettre aux actionnaires" (Onxeo publishes its new letter to shareholders) and explicitly states that the company announces the publication of its new letter to shareholders. It provides a link to consult this letter. A 'Lettre aux actionnaires' (Shareholder Letter) is a direct communication to investors, often summarizing performance or outlook, which aligns closely with the concept of an Investor Presentation (IP) or a general communication piece. However, given the specific options, the content is a direct communication piece announcing an update, rather than a formal regulatory filing like a 10-K or an ER. Since 'Lettre aux actionnaires' is not explicitly listed, I must choose the closest fit. It is a direct communication intended for investors, similar in purpose to an Investor Presentation (IP) or a general update. Given the context of a shareholder letter detailing plans for 2020 and clinical updates, 'Investor Presentation' (IP) is the most appropriate classification for this type of detailed, forward-looking communication aimed at investors, even if it's in letter format. It is not a short announcement of a report (RPA/RNS) because the content itself is substantial, detailing pipeline progress and future plans, not just pointing to an attached document.
2020-01-20 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.